Patrick Miailhes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6213909/publications.pdf

Version: 2024-02-01

1307594 1058476 14 339 7 14 citations g-index h-index papers 17 17 17 477 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. Clinical Infectious Diseases, 2022, 74, 1012-1021.	5.8	4
2	Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study. JMIR Research Protocols, 2021, 10, e24731.	1.0	6
3	Profiles of liver fibrosis evolution during longâ€term tenofovir treatment in HIVâ€positive patients coinfected with hepatitis B. Liver International, 2021, 41, 2874-2884.	3.9	4
4	Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 3009-3019.	3.0	4
5	Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV–hepatitis B coinfection. Aids, 2020, 34, 1943-1949.	2.2	2
6	Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection. Journal of Infectious Diseases, 2020, 221, 1826-1837.	4.0	8
7	Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. Antiviral Research, 2018, 149, 174-178.	4.1	4
8	Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV–HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. Journal of the International AIDS Society, 2017, 20, 21426.	3.0	37
9	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. Journal of Hepatology, 2016, 65, 683-691.	3.7	84
10	Rates and determinants of hepatitis B â€e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. Aids, 2015, 29, 1963-1973.	2.2	42
11	Therapeutic management and evolution of chronic hepatitis B: does <scp>HIV</scp> still have an impact? The <scp>EPIB</scp> 2012 study. Liver International, 2015, 35, 1950-1958.	3.9	16
12	Effect of Tenofovir With and Without Interferon on Hepatitis D Virus Replication in HIV–Hepatitis B Virus–Hepatitis D Virus-Infected Patients. AIDS Research and Human Retroviruses, 2013, 29, 1535-1540.	1.1	26
13	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology, 2013, 58, 912-922.	7. 3	37
14	Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. Journal of Hepatology, 2009, 50, 1074-1083.	3.7	63